相似文献
1
CTLA-4 co-receptor impacts on the function of Treg and CD8+ T-cell subsets.
Eur J Immunol. 2009 Mar;39(3):687-90. doi: 10.1002/eji.200939261.
2
CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent.
Blood. 2006 Dec 1;108(12):3818-23. doi: 10.1182/blood-2006-07-034066. Epub 2006 Aug 1.
3
Regulatory T cell (Treg) subsets return in patients with refractory lupus following stem cell transplantation, and TGF-beta-producing CD8+ Treg cells are associated with immunological remission of lupus.
J Immunol. 2009 Nov 15;183(10):6346-58. doi: 10.4049/jimmunol.0901773. Epub 2009 Oct 19.
4
Preferential development of CD4 and CD8 T regulatory cells in RasGRP1-deficient mice.
J Immunol. 2008 May 1;180(9):5973-82. doi: 10.4049/jimmunol.180.9.5973.
5
B7+ iris pigment epithelial cells convert T cells into CTLA-4+, B7-expressing CD8+ regulatory T cells.
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5376-84. doi: 10.1167/iovs.05-1354.
6
Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Cancer Res. 2013 Jun 15;73(12):3591-603. doi: 10.1158/0008-5472.CAN-12-4100. Epub 2013 Apr 30.
7
High IFN-gamma production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4).
J Immunol. 2007 Feb 15;178(4):2132-40. doi: 10.4049/jimmunol.178.4.2132.
8
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
J Immunol. 2005 Jun 1;174(11):6648-56. doi: 10.4049/jimmunol.174.11.6648.
9
CTLA-4+CD8+ T cells that encounter B7-2+ iris pigment epithelial cells express their own B7-2 to achieve global suppression of T cell activation.
J Immunol. 2004 Apr 1;172(7):4184-94. doi: 10.4049/jimmunol.172.7.4184.
10
Both regulatory T cells and antitumor effector T cells are primed in the same draining lymph nodes during tumor progression.
J Immunol. 2005 Oct 15;175(8):5058-66. doi: 10.4049/jimmunol.175.8.5058.
引用本文的文献
1
Targeting T helper 17 cells: emerging strategies for overcoming transplant rejection.
Clin Transplant Res. 2024 Dec 31;38(4):309-325. doi: 10.4285/ctr.24.0058.
2
Tryptophan Metabolism in Obesity: The Indoleamine 2,3-Dioxygenase-1 Activity and Therapeutic Options.
Adv Exp Med Biol. 2024;1460:629-655. doi: 10.1007/978-3-031-63657-8_21.
3
Dual Checkpoint Aptamer Immunotherapy: Unveiling Tailored Cancer Treatment Targeting CTLA-4 and NKG2A.
Cancers (Basel). 2024 Mar 4;16(5):1041. doi: 10.3390/cancers16051041.
4
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends.
Signal Transduct Target Ther. 2023 Aug 28;8(1):320. doi: 10.1038/s41392-023-01522-4.
5
CHI3L1 enhances melanoma lung metastasis regulation of T cell co-stimulators and CTLA-4/B7 axis.
Front Immunol. 2022 Dec 21;13:1056397. doi: 10.3389/fimmu.2022.1056397. eCollection 2022.
6
Optimal timing of steroid initiation in response to CTLA-4 antibody in metastatic cancer: A mathematical model.
PLoS One. 2022 Nov 10;17(11):e0277248. doi: 10.1371/journal.pone.0277248. eCollection 2022.
7
Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis.
Biomedicines. 2022 Jun 6;10(6):1334. doi: 10.3390/biomedicines10061334.
8
Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model.
PLoS One. 2022 Jan 11;17(1):e0262453. doi: 10.1371/journal.pone.0262453. eCollection 2022.
9
Microbeam Radiotherapy-A Novel Therapeutic Approach to Overcome Radioresistance and Enhance Anti-Tumour Response in Melanoma.
Int J Mol Sci. 2021 Jul 20;22(14):7755. doi: 10.3390/ijms22147755.
10
Single-cell transcriptome analysis identifies skin-specific T-cell responses in systemic sclerosis.
Ann Rheum Dis. 2021 Nov;80(11):1453-1460. doi: 10.1136/annrheumdis-2021-220209. Epub 2021 May 24.
本文引用的文献
1
CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin.
Eur J Immunol. 2009 Mar;39(3):883-93. doi: 10.1002/eji.200838770.
2
Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity.
J Immunol. 2009 Jan 1;182(1):274-82. doi: 10.4049/jimmunol.182.1.274.
3
CTLA-4 activation of phosphatidylinositol 3-kinase (PI 3-K) and protein kinase B (PKB/AKT) sustains T-cell anergy without cell death.
PLoS One. 2008;3(12):e3842. doi: 10.1371/journal.pone.0003842. Epub 2008 Dec 4.
4
CTLA-4 control over Foxp3+ regulatory T cell function.
Science. 2008 Oct 10;322(5899):271-5. doi: 10.1126/science.1160062.
5
CTLA4 expression is an indicator and regulator of steady-state CD4+ FoxP3+ T cell homeostasis.
J Immunol. 2008 Aug 1;181(3):1806-13. doi: 10.4049/jimmunol.181.3.1806.
6
The reverse stop-signal model for CTLA4 function.
Nat Rev Immunol. 2008 Feb;8(2):153-60. doi: 10.1038/nri2253.
7
CTLA-4 disrupts ZAP70 microcluster formation with reduced T cell/APC dwell times and calcium mobilization.
Eur J Immunol. 2008 Jan;38(1):40-7. doi: 10.1002/eji.200737423.
8
The expansion and maintenance of antigen-selected CD8(+) T cell clones.
Adv Immunol. 2007;96:103-39. doi: 10.1016/S0065-2776(07)96003-4.
9
High IFN-gamma production of individual CD8 T lymphocytes is controlled by CD152 (CTLA-4).
J Immunol. 2007 Feb 15;178(4):2132-40. doi: 10.4049/jimmunol.178.4.2132.
10
Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation.
J Immunol. 2006 Dec 1;177(11):7515-9. doi: 10.4049/jimmunol.177.11.7515.
Zotero 插件